PFE Insider Transactions
| Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-03-17 | LANKLER DOUGLAS M | officer: Executive Vice President | 53,860 | I-Discretionary | A | 24,938 | 40.10 | 1,000,013.80 |
| 2023-03-17 | BOURLA ALBERT | director, officer: Chairman & CEO | 175,790 | I-Discretionary | A | 74,813 | 40.10 | 3,000,001.30 |
| 2023-03-15 | BOURLA ALBERT | director, officer: Chairman & CEO | 100,977 | A-Award | A | 1,335 | 40.28 | 53,773.80 |
| 2023-03-15 | DAMICO JENNIFER B. | officer: SVP & Controller | 21,176 | A-Award | A | 451 | 40.28 | 18,166.28 |
| 2023-03-15 | DAMICO JENNIFER B. | officer: SVP & Controller | 9,003 | S-Sale | D | 9,912 | 40.02 | 396,678.24 |
| 2023-03-15 | JOHNSON RADY A | officer: Executive Vice President | 7,810 | A-Award | A | 78 | 40.28 | 3,141.84 |
| 2023-02-27 | SAHNI PAYAL | officer: Executive Vice President | 23,077 | F-InKind | D | 1,297 | 40.78 | 52,891.66 |
| 2023-02-27 | DAMICO JENNIFER B. | officer: SVP & Controller | 19,275 | F-InKind | D | 1,427 | 40.78 | 58,193.06 |
| 2023-02-27 | McDermott Michael | officer: Executive Vice President | 80,874 | F-InKind | D | 3,081 | 40.78 | 125,643.18 |
| 2023-02-25 | SAHNI PAYAL | officer: Executive Vice President | 0 | M-Exempt | D | 8,921 | 22.89 | 204,201.69 |
| 2023-02-25 | SAHNI PAYAL | officer: Executive Vice President | 24,374 | F-InKind | D | 3,967 | 43.44 | 172,326.48 |
| 2023-02-25 | SAHNI PAYAL | officer: Executive Vice President | 28,341 | F-InKind | D | 1,786 | 41.75 | 74,565.50 |
| 2023-02-25 | SAHNI PAYAL | officer: Executive Vice President | 30,127 | M-Exempt | A | 8,921 | 22.89 | 204,201.69 |
| 2023-02-25 | DAMICO JENNIFER B. | officer: SVP & Controller | 0 | M-Exempt | D | 11,150 | 22.89 | 255,223.50 |
| 2023-02-25 | DAMICO JENNIFER B. | officer: SVP & Controller | 20,702 | F-InKind | D | 4,958 | 43.44 | 215,375.52 |
| 2023-02-25 | DAMICO JENNIFER B. | officer: SVP & Controller | 25,660 | F-InKind | D | 2,233 | 41.75 | 93,227.75 |
| 2023-02-25 | DAMICO JENNIFER B. | officer: SVP & Controller | 27,893 | M-Exempt | A | 11,150 | 22.89 | 255,223.50 |
| 2023-02-25 | Hwang Angela | officer: President, Global Biopharma | 0 | M-Exempt | D | 20,273 | 22.89 | 464,048.97 |
| 2023-02-25 | Hwang Angela | officer: President, Global Biopharma | 29,778 | F-InKind | D | 9,015 | 43.44 | 391,611.60 |
| 2023-02-25 | Hwang Angela | officer: President, Global Biopharma | 38,793 | F-InKind | D | 5,748 | 41.75 | 239,979.00 |
| 2023-02-25 | Hwang Angela | officer: President, Global Biopharma | 44,541 | M-Exempt | A | 20,273 | 22.89 | 464,048.97 |
| 2023-02-25 | McDermott Michael | officer: Executive Vice President | 0 | M-Exempt | D | 14,178 | 22.89 | 324,534.42 |
| 2023-02-25 | McDermott Michael | officer: Executive Vice President | 83,955 | F-InKind | D | 6,305 | 43.44 | 273,889.20 |
| 2023-02-25 | McDermott Michael | officer: Executive Vice President | 90,260 | F-InKind | D | 2,839 | 41.75 | 118,528.25 |
| 2023-02-25 | McDermott Michael | officer: Executive Vice President | 93,099 | M-Exempt | A | 14,178 | 22.89 | 324,534.42 |
| 2023-02-25 | JOHNSON RADY A | officer: Executive Vice President | 0 | M-Exempt | D | 33,654 | 22.89 | 770,340.06 |
| 2023-02-25 | JOHNSON RADY A | officer: Executive Vice President | 93,637 | F-InKind | D | 14,966 | 43.44 | 650,123.04 |
| 2023-02-25 | JOHNSON RADY A | officer: Executive Vice President | 108,603 | F-InKind | D | 7,870 | 41.75 | 328,572.50 |
| 2023-02-25 | JOHNSON RADY A | officer: Executive Vice President | 116,473 | M-Exempt | A | 33,654 | 22.89 | 770,340.06 |
| 2023-02-25 | SUSMAN SALLY | officer: Executive Vice President | 0 | M-Exempt | D | 72,984 | 22.89 | 1,670,603.76 |
| 2023-02-25 | SUSMAN SALLY | officer: Executive Vice President | 154,311 | F-InKind | D | 32,455 | 43.44 | 1,409,845.20 |
| 2023-02-25 | SUSMAN SALLY | officer: Executive Vice President | 186,766 | F-InKind | D | 22,413 | 41.75 | 935,742.75 |
| 2023-02-25 | SUSMAN SALLY | officer: Executive Vice President | 209,179 | M-Exempt | A | 72,984 | 22.89 | 1,670,603.76 |
| 2023-02-25 | Dolsten Mikael | officer: President R&D | 354,145 | F-InKind | D | 37,078 | 41.75 | 1,548,006.50 |
| 2023-02-25 | BOURLA ALBERT | director, officer: Chairman & CEO | 309,058 | F-InKind | D | 43,419 | 41.75 | 1,812,743.25 |
| 2023-02-25 | LANKLER DOUGLAS M | officer: Executive Vice President | 135,146 | F-InKind | D | 26,389 | 41.75 | 1,101,740.75 |
| 2023-02-24 | DAMICO JENNIFER B. | officer: SVP & Controller | 16,383 | F-InKind | D | 360 | 41.75 | 15,030.00 |
| 2023-02-23 | Hwang Angela | officer: President, Global Biopharmaceu | 89,920 | A-Award | A | 89,920 | 42.30 | 3,803,616.00 |
| 2023-02-23 | Hwang Angela | officer: President, Global Biopharmaceu | 103,320 | A-Award | A | 103,320 | 42.30 | 4,370,436.00 |
| 2023-02-23 | SUSMAN SALLY | officer: Executive Vice President | 37,966 | A-Award | A | 37,966 | 42.30 | 1,605,961.80 |
| 2023-02-23 | SUSMAN SALLY | officer: Executive Vice President | 43,624 | A-Award | A | 43,624 | 42.30 | 1,845,295.20 |
| 2023-02-23 | SAHNI PAYAL | officer: Executive Vice President | 39,965 | A-Award | A | 39,965 | 42.30 | 1,690,519.50 |
| 2023-02-23 | SAHNI PAYAL | officer: Executive Vice President | 45,920 | A-Award | A | 45,920 | 42.30 | 1,942,416.00 |
| 2023-02-23 | Pao William | officer: Executive Vice President | 69,938 | A-Award | A | 69,938 | 42.30 | 2,958,377.40 |
| 2023-02-23 | Pao William | officer: Executive Vice President | 80,360 | A-Award | A | 80,360 | 42.30 | 3,399,228.00 |
| 2023-02-23 | McDermott Michael | officer: Executive Vice President | 39,965 | A-Award | A | 39,965 | 42.30 | 1,690,519.50 |
| 2023-02-23 | McDermott Michael | officer: Executive Vice President | 45,920 | A-Award | A | 45,920 | 42.30 | 1,942,416.00 |
| 2023-02-23 | MALIK AAMIR | officer: Executive Vice President | 89,920 | A-Award | A | 89,920 | 42.30 | 3,803,616.00 |
| 2023-02-23 | MALIK AAMIR | officer: Executive Vice President | 103,320 | A-Award | A | 103,320 | 42.30 | 4,370,436.00 |
| 2023-02-23 | LANKLER DOUGLAS M | officer: Executive Vice President | 69,938 | A-Award | A | 69,938 | 42.30 | 2,958,377.40 |
| 2023-02-23 | LANKLER DOUGLAS M | officer: Executive Vice President | 80,360 | A-Award | A | 80,360 | 42.30 | 3,399,228.00 |
| 2023-02-23 | JOHNSON RADY A | officer: Executive Vice President | 21,581 | A-Award | A | 21,581 | 42.30 | 912,876.30 |
| 2023-02-23 | JOHNSON RADY A | officer: Executive Vice President | 24,797 | A-Award | A | 24,797 | 42.30 | 1,048,913.10 |
| 2023-02-23 | Fonseca Lidia | officer: Executive Vice President | 37,966 | A-Award | A | 37,966 | 42.30 | 1,605,961.80 |
| 2023-02-23 | Fonseca Lidia | officer: Executive Vice President | 43,624 | A-Award | A | 43,624 | 42.30 | 1,845,295.20 |
| 2023-02-23 | Denton David M | officer: Chief Financial Officer & EVP | 89,920 | A-Award | A | 89,920 | 42.30 | 3,803,616.00 |
| 2023-02-23 | Denton David M | officer: Chief Financial Officer & EVP | 103,320 | A-Award | A | 103,320 | 42.30 | 4,370,436.00 |
| 2023-02-23 | Dolsten Mikael | officer: President R&D | 119,894 | A-Award | A | 119,894 | 42.30 | 5,071,516.20 |
| 2023-02-23 | Dolsten Mikael | officer: President R&D | 137,760 | A-Award | A | 137,760 | 42.30 | 5,827,248.00 |
| 2023-02-23 | BOURLA ALBERT | director, officer: Chairman & CEO | 359,681 | A-Award | A | 359,681 | 42.30 | 15,214,506.30 |
| 2023-02-23 | BOURLA ALBERT | director, officer: Chairman & CEO | 413,280 | A-Award | A | 413,280 | 42.30 | 17,481,744.00 |
| 2023-02-23 | DAMICO JENNIFER B. | officer: SVP & Controller | 10,591 | A-Award | A | 10,591 | 42.30 | 447,999.30 |
| 2023-02-23 | DAMICO JENNIFER B. | officer: SVP & Controller | 12,169 | A-Award | A | 12,169 | 42.30 | 514,748.70 |
| 2023-02-23 | DAMICO JENNIFER B. | officer: SVP & Controller | 16,743 | A-Award | A | 3,103 | 0.00 | 0.00 |
| 2023-02-22 | Hwang Angela | officer: President, Global Biopharmaceu | 0 | M-Exempt | A | 57,032 | 30.17 | 1,720,655.44 |
| 2023-02-22 | Hwang Angela | officer: President, Global Biopharmaceu | 24,268 | F-InKind | D | 34,718 | 43.70 | 1,517,176.60 |
| 2023-02-22 | Hwang Angela | officer: President, Global Biopharmaceu | 58,986 | F-InKind | D | 8,041 | 42.38 | 340,777.58 |
| 2023-02-22 | Hwang Angela | officer: President, Global Biopharmaceu | 67,027 | M-Exempt | A | 57,032 | 30.17 | 1,720,655.44 |
| 2023-02-22 | SUSMAN SALLY | officer: Executive Vice President | 0 | M-Exempt | A | 76,043 | 30.17 | 2,294,217.31 |
| 2023-02-22 | SUSMAN SALLY | officer: Executive Vice President | 136,195 | F-InKind | D | 46,291 | 43.70 | 2,022,916.70 |
| 2023-02-22 | SUSMAN SALLY | officer: Executive Vice President | 182,486 | F-InKind | D | 13,007 | 42.38 | 551,236.66 |
| 2023-02-22 | SUSMAN SALLY | officer: Executive Vice President | 195,493 | M-Exempt | A | 76,043 | 30.17 | 2,294,217.31 |
| 2023-02-22 | SAHNI PAYAL | officer: Executive Vice President | 0 | M-Exempt | A | 15,209 | 30.17 | 458,855.53 |
| 2023-02-22 | SAHNI PAYAL | officer: Executive Vice President | 21,206 | F-InKind | D | 9,259 | 43.70 | 404,618.30 |
| 2023-02-22 | SAHNI PAYAL | officer: Executive Vice President | 30,465 | F-InKind | D | 2,206 | 42.38 | 93,490.28 |
| 2023-02-22 | SAHNI PAYAL | officer: Executive Vice President | 32,671 | M-Exempt | A | 15,209 | 30.17 | 458,855.53 |
| 2023-02-22 | McDermott Michael | officer: Executive Vice President | 0 | M-Exempt | A | 13,307 | 30.17 | 401,472.19 |
| 2023-02-22 | McDermott Michael | officer: Executive Vice President | 78,921 | F-InKind | D | 8,101 | 43.70 | 354,013.70 |
| 2023-02-22 | McDermott Michael | officer: Executive Vice President | 87,022 | F-InKind | D | 1,935 | 42.38 | 82,005.30 |
| 2023-02-22 | McDermott Michael | officer: Executive Vice President | 88,957 | M-Exempt | A | 13,307 | 30.17 | 401,472.19 |
| 2023-02-22 | LANKLER DOUGLAS M | officer: Executive Vice President | 161,535 | F-InKind | D | 19,878 | 42.38 | 842,429.64 |
| 2023-02-22 | JOHNSON RADY A | officer: Executive Vice President | 0 | M-Exempt | A | 31,558 | 30.17 | 952,104.86 |
| 2023-02-22 | JOHNSON RADY A | officer: Executive Vice President | 82,819 | F-InKind | D | 19,211 | 43.70 | 839,520.70 |
| 2023-02-22 | JOHNSON RADY A | officer: Executive Vice President | 102,030 | F-InKind | D | 4,526 | 42.38 | 191,811.88 |
| 2023-02-22 | JOHNSON RADY A | officer: Executive Vice President | 106,556 | M-Exempt | A | 31,558 | 30.17 | 952,104.86 |
| 2023-02-22 | Dolsten Mikael | officer: President R&D | 391,223 | F-InKind | D | 32,592 | 42.38 | 1,381,248.96 |
| 2023-02-22 | BOURLA ALBERT | director, officer: Chairman & CEO | 352,477 | F-InKind | D | 61,994 | 42.38 | 2,627,305.72 |
| 2023-02-22 | DAMICO JENNIFER B. | officer: SVP & Controller | 0 | M-Exempt | A | 10,456 | 30.17 | 315,457.52 |
| 2023-02-22 | DAMICO JENNIFER B. | officer: SVP & Controller | 13,640 | F-InKind | D | 6,365 | 43.70 | 278,150.50 |
| 2023-02-22 | DAMICO JENNIFER B. | officer: SVP & Controller | 20,005 | F-InKind | D | 1,579 | 42.38 | 66,918.02 |
| 2023-02-22 | DAMICO JENNIFER B. | officer: SVP & Controller | 21,584 | M-Exempt | A | 10,456 | 30.17 | 315,457.52 |
| 2023-02-16 | DAMICO JENNIFER B. | officer: SVP & Controller | 20,707 | A-Award | A | 1,488 | 42.95 | 63,909.60 |
| 2023-02-16 | BOURLA ALBERT | director, officer: Chairman & CEO | 99,558 | A-Award | A | 2,037 | 42.95 | 87,489.15 |
| 2023-02-16 | JOHNSON RADY A | officer: Executive Vice President | 7,727 | A-Award | A | 228 | 42.95 | 9,792.60 |
| 2023-01-12 | BOURLA ALBERT | director, officer: Chairman & CEO | 96,522 | A-Award | A | 41 | 47.71 | 1,956.11 |
| 2023-01-12 | DAMICO JENNIFER B. | officer: SVP & Controller | 19,021 | A-Award | A | 121 | 47.71 | 5,772.91 |
| 2023-01-12 | JOHNSON RADY A | officer: Executive Vice President | 7,423 | A-Award | A | 16 | 47.71 | 763.36 |
| 2022-12-30 | Echevarria Joseph | director | 86,802.174 | A-Award | A | 902.615 | 51.24 | 46,249.99 |
| 2022-12-30 | NARAYEN SHANTANU | director | 113,786.006 | A-Award | A | 975.8 | 51.24 | 49,999.99 |
| 2022-12-30 | Quincey James | director | 27,026.854 | A-Award | A | 756.245 | 51.24 | 38,749.99 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.